Magnesium oxide is an inorganic compound that occurs in nature as the mineral periclase. In aqueous media combines quickly with water to form magnesium hydroxide. It is used as an antacid and mild laxative and has many nonmedicinal uses.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Succinylcholine | The therapeutic efficacy of Succinylcholine can be increased when used in combination with Magnesium oxide. |
| Metocurine iodide | The therapeutic efficacy of Metocurine iodide can be increased when used in combination with Magnesium oxide. |
| Gallamine triethiodide | The therapeutic efficacy of Gallamine triethiodide can be increased when used in combination with Magnesium oxide. |
| Cisatracurium | Magnesium oxide may increase the neuromuscular blocking activities of Cisatracurium. |
| Rocuronium | The therapeutic efficacy of Rocuronium can be increased when used in combination with Magnesium oxide. |
| Atracurium besylate | The therapeutic efficacy of Atracurium besylate can be increased when used in combination with Magnesium oxide. |
| Doxacurium | The therapeutic efficacy of Doxacurium can be increased when used in combination with Magnesium oxide. |
| Mivacurium | The therapeutic efficacy of Mivacurium can be increased when used in combination with Magnesium oxide. |
| Decamethonium | The therapeutic efficacy of Decamethonium can be increased when used in combination with Magnesium oxide. |
| Metocurine | The therapeutic efficacy of Metocurine can be increased when used in combination with Magnesium oxide. |
| Pancuronium | The therapeutic efficacy of Pancuronium can be increased when used in combination with Magnesium oxide. |
| Pipecuronium | The therapeutic efficacy of Pipecuronium can be increased when used in combination with Magnesium oxide. |
| Vecuronium | The therapeutic efficacy of Vecuronium can be increased when used in combination with Magnesium oxide. |
| Rapacuronium | The therapeutic efficacy of Rapacuronium can be increased when used in combination with Magnesium oxide. |
| Pyrantel | The therapeutic efficacy of Pyrantel can be increased when used in combination with Magnesium oxide. |
| Neosaxitoxin | The therapeutic efficacy of Neosaxitoxin can be increased when used in combination with Magnesium oxide. |
| Atracurium | The therapeutic efficacy of Atracurium can be increased when used in combination with Magnesium oxide. |
| Gallamine | The therapeutic efficacy of Gallamine can be increased when used in combination with Magnesium oxide. |
| Alcuronium | The therapeutic efficacy of Alcuronium can be increased when used in combination with Magnesium oxide. |
| Tubocurarine | The therapeutic efficacy of Tubocurarine can be increased when used in combination with Magnesium oxide. |
| Atazanavir | Magnesium oxide can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Bosutinib | Magnesium oxide can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefditoren | The serum concentration of Cefditoren can be decreased when it is combined with Magnesium oxide. |
| Dabigatran etexilate | Magnesium oxide can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dabrafenib | Magnesium oxide can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dasatinib | Magnesium oxide can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Delavirdine | Magnesium oxide can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Erlotinib | Magnesium oxide can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gefitinib | Magnesium oxide can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Itraconazole | Magnesium oxide can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Ledipasvir | Magnesium oxide can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Methylphenidate | Magnesium oxide can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. |
| Pazopanib | Magnesium oxide can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Riociguat | Magnesium oxide can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Calcitriol | The serum concentration of Magnesium oxide can be increased when it is combined with Calcitriol. |
| Calcifediol | The serum concentration of Magnesium oxide can be increased when it is combined with Calcifediol. |
| Paricalcitol | The serum concentration of Magnesium oxide can be increased when it is combined with Paricalcitol. |
| Dihydrotachysterol | The serum concentration of Magnesium oxide can be increased when it is combined with Dihydrotachysterol. |
| Alfacalcidol | The serum concentration of Magnesium oxide can be increased when it is combined with Alfacalcidol. |
| Seocalcitol | The serum concentration of Magnesium oxide can be increased when it is combined with Seocalcitol. |
| Inecalcitol | The serum concentration of Magnesium oxide can be increased when it is combined with Inecalcitol. |
| Becocalcidiol | The serum concentration of Magnesium oxide can be increased when it is combined with Becocalcidiol. |
| Eldecalcitol | The serum concentration of Magnesium oxide can be increased when it is combined with Eldecalcitol. |
| 1alpha,24S-Dihydroxyvitamin D2 | The serum concentration of Magnesium oxide can be increased when it is combined with 1alpha,24S-Dihydroxyvitamin D2. |
| Elocalcitol | The serum concentration of Magnesium oxide can be increased when it is combined with Elocalcitol. |
| Maxacalcitol | The serum concentration of Magnesium oxide can be increased when it is combined with Maxacalcitol. |
| Doxercalciferol | The serum concentration of Magnesium oxide can be increased when it is combined with Doxercalciferol. |
| 1alpha-Hydroxyvitamin D5 | The serum concentration of Magnesium oxide can be increased when it is combined with 1alpha-Hydroxyvitamin D5. |
| Deferiprone | Magnesium oxide can cause a decrease in the absorption of Deferiprone resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Dolutegravir | Magnesium oxide can cause a decrease in the absorption of Dolutegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Eltrombopag | Magnesium oxide can cause a decrease in the absorption of Eltrombopag resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Levothyroxine | Magnesium oxide can cause a decrease in the absorption of Levothyroxine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tolevamer | The risk or severity of adverse effects can be increased when Tolevamer is combined with Magnesium oxide. |
| Bisacodyl | The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Magnesium oxide. |
| Captopril | Magnesium oxide can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Cefpodoxime | The serum concentration of Cefpodoxime can be decreased when it is combined with Magnesium oxide. |
| Cefuroxime | The serum concentration of Cefuroxime can be decreased when it is combined with Magnesium oxide. |
| Chloroquine | Magnesium oxide can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Elvitegravir | Magnesium oxide can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Gabapentin enacarbil | The serum concentration of Gabapentin enacarbil can be decreased when it is combined with Magnesium oxide. |
| Hyoscyamine | Magnesium oxide can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Rifampin | Magnesium oxide can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mecamylamine | Magnesium oxide may decrease the excretion rate of Mecamylamine which could result in a higher serum level. |
| Memantine | Magnesium oxide may decrease the excretion rate of Memantine which could result in a higher serum level. |
| Penicillamine | Magnesium oxide can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Quinidine | Magnesium oxide may decrease the excretion rate of Quinidine which could result in a higher serum level. |
| Quinine | Magnesium oxide can cause a decrease in the absorption of Quinine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Sotalol | The serum concentration of Sotalol can be decreased when it is combined with Magnesium oxide. |
| Sulpiride | The therapeutic efficacy of Sulpiride can be increased when used in combination with Magnesium oxide. |
| Deferasirox | Magnesium oxide can cause a decrease in the absorption of Deferasirox resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Allopurinol | The therapeutic efficacy of Allopurinol can be decreased when used in combination with Magnesium oxide. |
| Fexofenadine | Magnesium oxide can cause a decrease in the absorption of Fexofenadine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Raltegravir | Magnesium oxide can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Halofantrine | Magnesium oxide can cause a decrease in the absorption of Halofantrine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Misoprostol | The risk or severity of adverse effects can be increased when Magnesium oxide is combined with Misoprostol. |
| Mesalazine | Magnesium oxide can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Mycophenolic acid | The serum concentration of Mycophenolic acid can be decreased when it is combined with Magnesium oxide. |
| Cysteamine | The bioavailability of Cysteamine can be decreased when combined with Magnesium oxide. |
| Ketoconazole | Magnesium oxide can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy. |
| Tramadol | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Tramadol. |
| Trospium | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Trospium. |
| Oxyphenonium | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Oxyphenonium. |
| Benzatropine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Benzatropine. |
| Ziprasidone | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Ziprasidone. |
| Disopyramide | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Disopyramide. |
| Amitriptyline | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Amitriptyline. |
| Ipratropium | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Ipratropium. |
| Olanzapine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Olanzapine. |
| Metixene | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Metixene. |
| Terfenadine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Terfenadine. |
| Buclizine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Buclizine. |
| Clozapine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Clozapine. |
| Doxylamine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Doxylamine. |
| Trihexyphenidyl | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Trihexyphenidyl. |
| Oxyphencyclimine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Oxyphencyclimine. |
| Procyclidine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Procyclidine. |
| Profenamine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Profenamine. |
| Cyproheptadine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Cyproheptadine. |
| Imipramine | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Imipramine. |
| Methscopolamine bromide | The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Methscopolamine bromide. |